PET-CT After — Lung Cancer Treatment

There is no single waiting period that applies to everyone — it depends on what treatment you had, how your body has responded, and your oncologist's clinical judgement. After radiotherapy in particular, your team will want inflammation in the lung to settle before scanning, because inflamed tissue absorbs the tracer actively and can produce a misleading result. Expect the conversation about timing to happen at your first follow-up appointment after treatment ends, not immediately when the last session is finished.

Not necessarily, and this is one of the hardest parts of post-treatment scanning. A bright area could be active cancer, but it could also be radiation-induced inflammation, post-treatment scarring, or a TB granuloma — all of which are common in India and all of which can look very similar on PET-CT. Your oncologist will consider where the area is, how bright it is, how it compares to your previous scans, and whether a biopsy is needed before drawing any conclusion.

No imaging test can confirm with certainty that no cancer cells remain. PET-CT is highly sensitive to metabolic activity, but very small clusters of cancer cells may not produce enough signal to be visible, and areas of activity on the scan can turn out not to be cancer. What it does well is identify areas that need further investigation and guide where a biopsy should be taken. A normal PET-CT after treatment is reassuring — it is not a guarantee.

Yes, and it is important to tell your team. Old TB scars can remain metabolically active on PET-CT even without any active infection. Active TB — including cases not yet diagnosed — will appear bright on the scan and can be mistaken for cancer spread to lymph nodes or new deposits elsewhere. Your clinical team in India is experienced with this differential. Knowing your TB history, including any past treatment, allows them to interpret the scan with that context in mind.

The whole body. This is one of the main advantages of PET-CT for follow-up after lung cancer. In a single session, it shows how the original tumour has responded, whether nearby lymph nodes are still metabolically active, and whether there is any activity at distant sites — bones, liver, adrenal glands — that needs attention. Covering all of this in one appointment means a more complete picture than several separate investigations would give.

An unclear result is treated as a clinical question, not a final answer. Depending on where the area is and how concerning it looks, your oncologist may recommend a biopsy of the site, a repeat scan after a further period, or discussion at the multidisciplinary team meeting — where oncologists, radiologists and nuclear medicine specialists review the case together. Ask specifically what the next step is and what question it is trying to answer. You will not be left without a plan.